| Objective:By observing the clinical efficacy of Shenlingbaizhu powder combined with anti-vascular endothelial growth factor in the treatment of age-related macular degeneration secondary macular edema,to provide a basis for new treatment and the clinical application of AMD-ME patients.Method:The cases in this study come from 60 cases and 60 eyes of patients with spleen-deficiency and dampness-type AMD-ME who met the inclusion criteria in Fujian Second People’s Hospital and Fuzhou Eye Hospital.They were randomly divided into two groups.The control group was treated with intravitreal injection of Leizhumab(0.5mg)once,the treatment group was given a course of Shenlingbaizhu powder on the basis of the control group.The best corrected visual acuity and central macular thickness of the two groups were observed at 1 week,1 month,2months and 3 months after operation,the fundus condition in two grousps after 3 months of treatment were observed.Result:1.Comparison of the best corrected visual acuity between the two groupsBefore treatment,the BCVA(Log MAR)of the two group were 0.75±0.35 and 0.82±0.28 respectively,with no significant difference(P>0.05).One week after treatment,it was0.54±0.26,0.62±0.26 respectively.One month after treatment,it was 0.42±0.17,0.48±0.19respectively(P>0.05).There were no significant difference between the two groups(P>0.05).Two months after treatment,the values were 0.35±0.23 and 0.48±0.27 respectively,and the treatment group was superior to the control group with statistically significant difference(P<0.05).Three months after treatment,it was 0.27±0.23 in the treatment group which was better than 0.42±0.30 in the control group,and the difference was statistically significant(P<0.05).2.Comparison of retinal thickness in macular fovea between two groupsThe CMT values of the treatment group were 514.47±119.26 and the control group were531.20±83.20 before treatment,446.33±103.50 and 475.33±79.41 after one week of treatment,388.97±75.94 and 431.60±63.62 after one months of treatment,all of its have no significant difference(P > 0.05).Two months after treatment,the values were 361.63±83.68 and418.67±93.13 respectively,and the treatment group were superior to the control group with statistically significant difference(P<0.05).Three months after treatment,it was 334.93±89.37 in the treatment group which was better than 405.27±104.65 in the control group,and the difference was statistically significant(P<0.05).3.Comparison of fundus between the two groups 3 months after treatmentThree months after treatment,9 cases of retinal hemorrhage and exudation were basically absorbed in the treatment group,19 cases were partially absorbed,2 cases were not absorbed or even aggravated.In the control group,5 cases of retinal hemorrhage and exudation were basically absorbed,16 cases were partially absorbed,and 9 cases were not absorbed or even aggravated.The curative effect of the treatment group was better than that of the control group,and the difference was statistically significant(P<0.05).4.Comparison of clinical efficacy between two groups of patientsThree months after treatment,the curative effects of the two groups were as follows: 9 cases(30%)were markedly effective,19 cases(63.33%)were effective,2 cases(6.67%)were ineffective in the treatment group,and the total effective rate was 93.33%.In the control group,5cases(16.67%)were markedly effective,16 cases(53.33%)were effective,and 9 cases(30.00%)were ineffective,with a total effective rate of 70.00%.The curative effect of the treatment group is better than that of the control group,and the difference is statistically significant(P<0.05).Conclusion:Shenling Baizhu Powder combined with intravitreal injection of Rayzumab and intracavity injection of Rayzumab alone have a significant effect on AMD-ME.But Shenling Baizhu Powder combined with intravitreal injection of Rayzumab in the treatment of AMD-ME is better than intracavity injection of Rayzumab. |
PDF Full Text Request